Lobe Sciences Concludes Private Placement to Raise CAD $341,425

Lobe Sciences Ltd., a Vancouver-based biopharmaceutical company, has successfully closed a non-brokered private placement. The offering involved the sale of 8,535,625 common shares at $0.04 per share, generating gross proceeds of CAD $341,425. The completion of this offering follows an announcement made on July 29, 2025.

The shares issued in this placement are subject to a statutory holding period of four months and one day. Notably, these securities are not registered under the U.S. Securities Act of 1933, rendering them restricted from offer or sale in the United States without necessary registration or exemption.

Lobe Sciences aims to advance therapeutics for rare and underserved diseases. The company plans to use the proceeds to support ongoing development operations. Future updates on their progress will be provided as necessary approvals and further developments ensue.